SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?


To: richardred who wrote (938)12/16/2005 9:54:24 AM
From: richardred  Read Replies (2) | Respond to of 7243
 
J & J can buy a lot of smaller companies for 20+ billion. If it decides not to pursue Guidant. They look to be starting!

Johnson & Johnson to Acquire Animas
Friday December 16, 9:30 am ET
Johnson & Johnson to Acquire Animas for About $518M to Capitalize on Diabetes Treatment Demand

NEW YORK (AP) -- Health products maker Johnson & Johnson said Friday it has agreed to acquire Animas Corp., an insulin delivery company, for about $518 million to capitalize on the growing demand for diabetes treatment.

The acquisition will give Johnson & Johnson immediate entry in the fast-growing insulin delivery pump market, the company said.

J&J, which is based in New Brunswick, N.J., said it would pay $24.50 for each Animas share, a 35 percent premium to Animas' Thursday closing stock price on the Nasdaq. Shares of Animas jumped $5.85, or 32 percent, to $24.05 before the start of regular trading Friday.

The boards of both J&J and Animas have approved the deal, which is expected to close in next year's first quarter, pending approval from antitrust regulators and Animas shareholders.

Once the acquisition closes, Animas, based in West Chester, Pa., will operate as a stand-alone entity under LifeScan Inc., a J&J subsidiary that sells blood glucose monitoring systems.

The deal comes as Johnson & Johnson and Boston Scientific are each trying to buy medical device maker Guidant Corp.

Boston Scientific announced this month it would offer $25 billion for Guidant after J&J lowered its initial $25.4 billion bid to $21.5 billion following months of recalls of Guidant products.



To: richardred who wrote (938)1/6/2006 1:59:06 AM
From: richardred  Read Replies (5) | Respond to of 7243
 
ARRO earnings were a disappointment. I'll hold for now. Medical devices still ok to play IMO.

Diagnostic Ultrasound, Maker of BladderScan(R) Bladder Volume Instruments, Acquires GlideScope(R) Manufacturer, Saturn Biomedical Systems
Thursday January 5, 11:00 am ET

BOTHELL, Wash., Jan. 5 /PRNewswire/ -- Diagnostic Ultrasound Corporation ("DU"), a rapidly growing provider of handheld ultrasound instruments, today announced the acquisition of Saturn Biomedical Systems, Inc., the Canada-based manufacturer of the innovative GlideScope® Video Laryngoscope.

Saturn's GlideScope® Video Laryngoscope (GVL(TM)) assists with anesthesia intubations in surgery and in the ER. Designed and developed to make the passage of a breathing tube into the airway during anesthesia safe, reliable and easy, GlideScope® is a significant improvement over the traditional laryngoscope widely used for this purpose. With its integrated camera, patented anti-fogging mechanism, and patented 50 to 60 degree viewing range, GlideScope® enables visual control of the endotracheal tube in its trajectory toward the airway. The GlideScope® micro-video technology provides a clear picture of the larynx and vocal cords on a display monitor, further assisting proper endotracheal tube placement.

"The Saturn acquisition is a great step forward for our team, the Saturn team, and GlideScope® technology," said Gerald McMorrow, CEO, Founder & Chairman of the Board of Diagnostic Ultrasound. "GlideScope® solves an important, life-threatening medical problem. The patented GlideScope® technology improves outcomes for difficult airway patients in surgery and in the ER, and it offers a new standard of care in airway management for Anesthesiologists. We're excited about bringing this improved technology to Acute Care, and we're looking forward to a continued expansion of our product offerings in this rapidly growing market segment."

An estimated 40-50 million anesthesia procedures are administered each year in North America, and in up to fifty percent of cases, it is necessary for anesthesia and emergency specialists to place an endotracheal tube to control respiration. Many of the current laryngoscopes require "line of sight" maneuvers that induce neck flexion, head extension, laryngeal depression and other movements that can cause stress to patients.

"As a Vascular and General Surgeon, I've seen first hand how minimally invasive video technology can revolutionize how surgeons operate," said Dr. John Pacey, co-founder and CEO of Saturn Biomedical Systems. "Observing an extremely difficult intubation by two skilled Anesthesiologists over a period of 25 minutes confirmed the need for an improved viewing range and inspired the use of micro-video technology in the invention of the GlideScope®. The benefits of video laryngoscopy are now recognized by several prominent Anesthesiologists and more are embracing the technology every day. Combining forces with Diagnostic Ultrasound will facilitate an even faster deployment of GlideScope® technology into the OR -- a "win" for both Anesthesiologists and their patients."

Diagnostic Ultrasound specializes in application-specific ultrasound devices for the Urology, Acute Care, Primary Care, and Extended Care markets. The company is best known for its BladderScan® bladder volume instruments, which are clinically proven to help eliminate unnecessary catheterization and reduce rates of urinary tract infection. The noninvasive, easy to use BladderScan® has become the standard of care for many health care providers. The FloPoint(TM) Uroflow System and ScanPoint® Software and Imaging Services round out the company's current product line.

Diagnostic Ultrasound, which is privately held, recently received the first phase of a $34 million infusion of capital from DW Healthcare Partners, L.P. and Rho Private Equity, L.P. to fund both internal and acquisition- focused growth initiatives.

About Diagnostic Ultrasound

Diagnostic Ultrasound fills a unique niche in the medical industry, specializing in the development of handheld, ultrasound devices. The company's mission is to advance patient care by making noninvasive instruments and devices more accessible to healthcare providers. Founded in 1984, Diagnostic Ultrasound has grown from a small start-up venture to a thriving and profitable international corporation. Experiencing double-digit growth in 2005, Diagnostic Ultrasound was recently ranked among the fastest growing technology companies in Washington State in Deloitte's prestigious "Technology Fast 50" program. Diagnostic Ultrasound is headquartered in Bothell, Washington. Following the acquisition of Saturn, the company has approximately 200 employees worldwide. For more information, please visit www.dxu.com.

About Saturn Biomedical Systems

Saturn Biomedical Systems Inc. is a privately held company based in Burnaby, British Columbia, Canada. Founded in January 1999 by Dr. John A. Pacey, MD FRCS© and Mr. Awni Ayoubi, P. Eng, Saturn Biomedical specializes in practical research, development and supply of new and improved medical devices and instruments for use in tandem with surgical procedures. The company's innovative GlideScope® Video Laryngoscope product line has experienced rapid sales growth since its introduction in 2001. Saturn, which is profitable, has further new product introductions planned.

NOTE: BladderScan® and ScanPoint® are registered trademarks and FloPoint(TM) is a trademark of Diagnostic Ultrasound Corporation. GlideScope® is a registered trademark and GVL(TM) is a trademark of Saturn Biomedical Systems. All rights reserved.

Contact: Jessica McMorrow, PR Specialist, Diagnostic Ultrasound Corp., 425-867-1348, Ext. 1417. Alternate Contact: Jane Mueller, VP of Marketing, Diagnostic Ultrasound Corp., 425-867-1348, Ext. 1301.

Source: Diagnostic Ultrasound Corporation

biz.yahoo.com



To: richardred who wrote (938)3/31/2006 10:03:04 AM
From: richardred  Read Replies (1) | Respond to of 7243
 
Downgrade yesterday/upgrade today/Same firm/a little indecision?
I don't see this to often.

finance.yahoo.com

Brean Murray Cuts Arrow International to Hold
Analyst Arnold Kaufman cites the company's second quarter results



Analyst Arnold Kaufman says second quarter gross margins were negatively impacted by forex and training costs. The majority of workers at the company's (new) Mexico plant are new, and therefore require a longer training period than originally anticipated. He notes the company lowered its $480 million to $490 million fiscal year 2006 (ending August) revenue guidance to $476 million to $484 million, and its $1.30 to $1.35 earnings per share (EPS) to between $1.26 and $1.30. He cut his $1.32 fiscal year 2006 EPS estimate to $1.26. Due to slower than anticipated improvement in fundamentals, he downgrades the stock.